%0 Journal Article
%A von Hagens, Cornelia
%A Walter-Sack, Ingeborg
%A Goeckenjan, Maren
%A Osburg, Julia
%A Storch-Hagenlocher, Brigitte
%A Sertel, Serkan
%A Elsässer, Michael
%A Remppis, Bjoern Andrew
%A Edler, Lutz
%A Munzinger, Judith
%A Efferth, Thomas
%A Schneeweiss, Andreas
%A Strowitzki, Thomas
%T Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2).
%J Breast cancer research and treatment
%V 164
%N 2
%@ 1573-7217
%C Dordrecht [u.a.]
%I Springer Science + Business Media B.V.
%M DKFZ-2017-01318
%P 359 - 369
%D 2017
%X The antimalarial drug artesunate (ART) is a promising candidate for cancer treatment as it displays anticancer effects in various models. While in short-term treatment of malaria, an excellent safety profile has been found for ART, the potential long-term treatment of cancer patients demands a phase I dose-finding clinical trial determining the daily ART dose which would be well tolerated as add-on therapy.Patients with metastatic breast cancer were to receive either 100 or 150 or 200 mg oral ART daily as add-on to their guideline-based oncological therapy for a study period of four weeks with frequent clinical and laboratory monitoring until 4-8 weeks thereafter. According to the statistical design, recruitment was scheduled in groups of three patients in order not to miss a more than 33
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:28439738
%R 10.1007/s10549-017-4261-1
%U https://inrepo02.dkfz.de/record/124441